Literature DB >> 6107451

Carnitine improves lipid anomalies in haemodialysis patients.

B Lacour, S Di Giulio, J Chanard, C Ciancioni, M Haguet, B Lebkiri, C Basile, T Drüeke, R Assan, J L Funck-Brentano.   

Abstract

51 chronic haemodialysis patients with hypertriglyceridaemia were given a daily oral dose of 2.4 g D,L-carnitine for 30 days to investigate a possible hypolipaemic effect. After 30 days' D,L-carnitine treatment the mean (+/- SEM) serum triglyceride concentration had decreased significantly from 3.50 +/- 0.39 to 2.87 +/- 0.27 mmol/l. Serum total cholesterol did not change. However, HDL cholesterol increased significantly from 0.89 +/- 0.05 to 1.35 +/- 0.07 mmol/l. This decrease in serum triglycerides and return of HDL cholesterol to normal levels in haemodialysis patients may be the result of correction of carnitine deficiency. Such treatment could reduce the risk factors for atherosclerosis and coronary-artery disease in uraemic patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107451     DOI: 10.1016/s0140-6736(80)90384-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

3.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

Review 4.  Mitigating the pro-oxidant state and melanogenesis of Retinitis pigmentosa: by counteracting mitochondrial dysfunction.

Authors:  Giovanni Pagano; Federico V Pallardó; Alex Lyakhovich; Luca Tiano; Marco Trifuoggi
Journal:  Cell Mol Life Sci       Date:  2021-10-31       Impact factor: 9.261

5.  The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.

Authors:  A J Williams; F Baker; J Walls
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 6.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

7.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

8.  Effects of combined treatment with simvastatin and L-carnitine on triglyceride levels in diabetic patients with hyperlipidaemia.

Authors:  Francesco Brescia; Elisabetta Balestra; Maria Grazia Iasella; Aurelia Bellomo Damato
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

9.  Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.

Authors:  W A Gahl; I Bernardini; M Dalakas; W B Rizzo; G S Harper; J M Hoeg; O Hurko; J Bernar
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

10.  Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients.

Authors:  Celalettin Koşan; Lale Sever; Nil Arisoy; Salim Calişkan; Ozgür Kasapçopur
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.